Nutanix (NTNX) Gains as Results and Outlook Come Ahead of Expectations, Analyst Raises PT on Rising Confidence

Nutanix (NTNX) PT Raised to $50 at Susquehanna

Susquehanna analyst Mehdi Hosseini raised the price target on Nutanix (NASDAQ: NTNX) to $50.00 (from $38.00) while maintaining a Positive rating following earnings.

The analyst commented, "We are updating estimates/price target following Nutanix Jul-Q report and conference call. All in all, the... More

Nutanix (NTNX) PT Raised to $64 at Needham & Company

Needham & Company analyst Jack Andrews raised the price target on Nutanix (NASDAQ: NTNX) to $64.00 (from $61.00) while maintaining a Buy rating.

The analyst commented, "NTNX reported strong 4QFY21 results as multiple metrics (ACV billings, total billings, emerging product billings, million-dollar deals) all... More

Nutanix (NTNX) Shift to ARR Will be a Positive Over Time - RBC

RBC Capital analyst Matthew Hedberg reiterated an Outperform rating and $50.00 price target on Nutanix (NASDAQ: NTNX) after the company delivered a strong quarter with ACV billings of $176.3M, +26% y/y, vs. consensus at $172M, +23%. Growth improved from Q3/21 where the increase was +18%. Management noted strong... More

Nutanix (NTNX) Tops Q4 EPS by 16c

Nutanix (NASDAQ: NTNX) reported Q4 EPS of ($0.26), $0.16 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $390.72 million versus the consensus estimate of $362.88 million.

Our fourth quarter was a strong end to an excellent fiscal year, which was marked by... More

Nutanix (NTNX) Earnings Preview, BofA Securities Sees Billings Upside

BofA Securities analyst Wamsi Mohan reiterated a Buy rating and $54.00 price target on Nutanix (NASDAQ: NTNX) ahead of F4Q21 results on Sep 1st, AMC. The analyst is looking for ACV billings of $173.6mn, slightly above the mid-point of the guidance range of... More